Abstract
Abstract A novel zoledronic acid (ZL) derivative, 1-hydroxy-2-(2,4-dimethyl-1H-imidazol-1-yl)-ethane-1,1-diyldiphosphonic acid (DMIDP, dimezoledronate), was successfully prepared and labeled with 99mTc in a high labeling yield. The biodistribution in mice shows that 99mTc-DMIDP has significant advantage regarding bone resorption and clearance from soft tissues compared with 99mTc-ZL and the clinically widely-used bone-imaging agent 99mTc-MDP (methylenediphosphonic acid). Kinetics of blood clearance displayed that distribution half-life (T 1/2α ) and elimination half-life (T 1/2β ) of 99mTc-DMIDP were 2.53 min and 23.53 min, while those of 99mTc-ZL were 2.28 and 52.63 min, respectively. Excellent images of the rabbit skeleton can be quickly obtained from 99mTc-DMIDP, which was faster than 99mTc-ZL and 99mTc-MDP. The present findings indicate that 99mTc-DMIDP possesses excellent potential for application as a novel bone scanning agent.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
